A bispecific decoy receptor VEGFR-EGFR/Fc binding EGF-like ligands and VEGF shows potent antitumor efficacy

References

• Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res. 2007;5(3):203–220.
   PubMed Web of Science ®Google Scholar
• Rowinsky EK. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med. 2004;55:433–457.
   PubMed Web of Science ®Google Scholar
• Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 2009;21(2):177–184.
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res. 2019;139:395–411.
   PubMed Web of Science ®Google Scholar
• Cao HY, Guo XF, Zhu XF, et al. A ligand-based and enediyne-energized bispecific fusion protein targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer. Oncol Rep. 2017;37(6):3329–3340.
   PubMed Web of Science ®Google Scholar
• Moradi-Kalbolandi S, Hosseinzade A, Salehi M, et al. Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to pan HER. J Pharm Pharmacol. 2018;70(7):841–854.
   PubMed Web of Science ®Google Scholar
• de Mello RA, Neves NM, Tadokoro H, et al. New target therapies in advanced non-small cell lung cancer: a review of the literature and future perspectives. J Clin Med. 2020;9(11):3543.
   PubMed Web of Science ®Google Scholar
• Douillard J-Y, Pirker R, O'Byrne KJ, et al. Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer. J Thorac Oncol. 2014;9(5):717–724.
   PubMed Web of Science ®Google Scholar
• Carrera S, Buque A, Azkona E, et al. Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies. Clin Transl Oncol. 2014;16(4):339–350.
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–1186.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Adjei AA. Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. Oncologist. 2015;20(6):660–673.
   PubMed Web of Science ®Google Scholar
• Sinicrope FA, Okamoto K, Kasi PM, et al. Molecular biomarkers in the personalized treatment of colorectal cancer. Clin Gastroenterol Hepatol. 2016;14(5):651–658.
   PubMed Web of Science ®Google Scholar
• Sia D, Alsinet C, Newell P, et al. VEGF signaling in cancer treatment. Curr Pharm Des. 2014;20(17):2834–2842.
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–2342.
   PubMed Web of Science ®Google Scholar
• Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin®) in cancer treatment: a review of 15reatment: oi.org/https://doi.org/10.1056/NEJMoa032691" vorin for. Cancer Treat Rev. 2020;86:102017.
   PubMed Web of Science ®Google Scholar
• Pore N, Jiang Z, Gupta A, et al. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res. 2006;66(6):3197–3204.
   PubMed Web of Science ®Google Scholar
• Bianco R, Rosa R, Damiano V, et al. Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. Clin Cancer Res. 2008;14(16):5069–5080.
   PubMed Web of Science ®Google Scholar
• Naumov GN, Nilsson MB, Cascone T, et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res. 2009;15(10):3484–3494.
   PubMed Web of Science ®Google Scholar
• Nakade J, Takeuchi S, Nakagawa T, et al. Triple inhibition of EGFR, met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation. J Thorac Oncol. 2014;9(6):775–783.
   PubMed Web of Science ®Google Scholar
• Peravali M, Wang H, Kim C, et al. Combined inhibition of EGFR and VEGF pathways in patients with EGFR-mutated non-small cell lung cancer: a systematic review and Meta-analysis. Curr Oncol Rep. 2020;22(12):119.
   PubMed Web of Science ®Google Scholar
• Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20(5):625–635.
   PubMed Web of Science ®Google Scholar
• Kitagawa C, Mori M, Ichiki M, et al. Gefitinib plus bevacizumab vs. gefitinib alone for EGFR mutant non-squamous non-small cell lung cancer. In Vivo. 2019;33(2):477–482.
   PubMed Web of Science ®Google Scholar
• Lee SH, Lee JK, Ahn MJ, et al. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial. Ann Oncol. 2017;28(2):292–297.
   PubMed Web of Science ®Google Scholar
• Wells SA Jr., Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30(2):134–141.
   PubMed Web of Science ®Google Scholar
• Pennell NA Jr., Lynch TJ. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist. 2009;14(4):399–411.
   PubMed Web of Science ®Google Scholar
• Syed YY, McKeage K. Aflibercept: a review in metastatic colorectal cancer. Drugs. 2015;75(12):1435–1445.
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Papadopoulos KP, Patnaik A, et al. A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors. Ann Oncol. 2016;27(3):526–532.
   PubMed Web of Science ®Google Scholar
• Sarup J, Jin P, Turin L, et al. Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts. Mol Cancer Ther. 2008;7(10):3223–3236.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick VD, Pisacane PI, Vandlen RL, et al. Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4. FEBS Lett. 1998;431(1):102–106.
   PubMed Web of Science ®Google Scholar
• Davis-Smyth T, Chen H, Park J, et al. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J. 1996;15(18):4919–4927.
   PubMed Web of Science ®Google Scholar
• Yu L, Liang XH, Ferrara N. Comparing protein VEGF inhibitors: in vitro biological studies. Biochem Biophys Res Commun. 2011;408(2):276–281.
   PubMed Web of Science ®Google Scholar
• Brown PM, Debanne MT, Grothe S, et al. The extracellular domain of the epidermal growth factor receptor. Studies on the affinity and stoichiometry of binding, receptor dimerization and a binding-domain mutant. Eur J Biochem. 1994;225(1):223–233.
   PubMedGoogle Scholar
• Holash J, Davis S, Papadopoulos N, et al. VEGF-trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99(17):11393–11398.
   PubMed Web of Science ®Google Scholar
• Shen Y, Zeng L, Novosyadlyy R, et al. A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation. MAbs. 2015;7(5):931–945.
   PubMed Web of Science ®Google Scholar